IMMX
Immix Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.22
+3.01%Next report
Analyst consensus
- Next report date
- Nov 6, 2026
- EPS estimate
- -$0.19
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 7, 2026
- EPS actual
- -$0.18
- EPS estimate
- -$0.17
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -15.5%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $25
- PT range
- $19 – $30
- Analysts
- 4
4 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 7, 2026 | -$0.17 | -$0.18 | Miss -5.88% | — |
| May 7, 2026 | -$0.18 | -$0.18 | Miss -1.41% | — |
| Mar 25, 2026 | -$0.21 | -$0.27 | Miss -28.57% | — |
| Nov 7, 2025 | -$0.19 | -$0.24 | Miss -26.32% | — |
| Aug 8, 2025 | -$0.21 | -$0.22 | Miss -4.76% | — |
| May 8, 2025 | -$0.23 | -$0.15 | Beat 34.78% | — |
| Mar 24, 2025 | -$0.25 | -$0.16 | Beat 36.00% | $96.3K |
| May 9, 2024 | -$0.23 | -$0.22 | Beat 4.35% | — |
| Mar 29, 2024 | -$0.23 | -$0.24 | Miss -4.35% | $4.8K |
| Nov 9, 2023 | -$0.23 | -$0.23 | In line | — |
| Aug 11, 2023 | -$0.17 | -$0.24 | Miss -41.18% | — |
| May 12, 2023 | -$0.14 | -$0.18 | Miss -28.57% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 6, 2026